Aligos Therapeutics (ALGS) Equity Ratio (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Equity Ratio for 5 consecutive years, with 0.6 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 246.32% year-over-year to 0.6, compared with a TTM value of 0.6 through Dec 2025, up 246.32%, and an annual FY2025 reading of 0.6, up 246.32% over the prior year.
- Equity Ratio was 0.6 for Q4 2025 at Aligos Therapeutics, down from 0.65 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.83 in Q1 2021 and bottomed at 0.41 in Q4 2024.
- Average Equity Ratio over 5 years is 0.64, with a median of 0.7 recorded in 2023.
- The sharpest move saw Equity Ratio plummeted 168.02% in 2024, then soared 246.32% in 2025.
- Year by year, Equity Ratio stood at 0.78 in 2021, then dropped by 9.76% to 0.71 in 2022, then fell by 14.2% to 0.61 in 2023, then tumbled by 168.02% to 0.41 in 2024, then skyrocketed by 246.32% to 0.6 in 2025.
- Business Quant data shows Equity Ratio for ALGS at 0.6 in Q4 2025, 0.65 in Q3 2025, and 0.76 in Q2 2025.